Drugs / PF-06952229
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03685591 | Oct 2018 → Mar 2022 | breast neoplasm, colorectal neoplasm, liver and intrahepatic bile duct neoplasm, melanoma +5 | Pfizer | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06952229 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03685591 ↗ |
| Modality | Small molecule | — CHEMBL5095192 ↗ |